Financhill
Sell
47

RGEN Quote, Financials, Valuation and Earnings

Last price:
$141.66
Seasonality move :
4.98%
Day range:
$138.32 - $142.66
52-week range:
$102.97 - $182.52
Dividend yield:
0%
P/E ratio:
633.44x
P/S ratio:
12.24x
P/B ratio:
4.00x
Volume:
573.7K
Avg. volume:
907.1K
1-year change:
-14.91%
Market cap:
$8B
Revenue:
$634.4M
EPS (TTM):
-$0.41

Price Performance History

Performance vs. Valuation Benchmarks

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Competitors

Company Revenue Forecast Earnings Forecast Revenue Growth Forecast Earnings Growth Forecast Analyst Price Target Median
RGEN
Repligen
$163.8M $0.35 9.86% 286.84% $183.13
BAX
Baxter International
$2.6B $0.48 -25.63% 590.29% $38.80
CATX
Perspective Therapeutics
$143.9K -$0.27 -- -35.77% $14.3929
ICUI
ICU Medical
$574.2M $1.28 1.32% 316.67% $186.40
MASS
908 Devices
$11.9M -$0.27 19.12% -24.24% $5.50
UFPT
UFP Technologies
$139.9M $2.01 33.42% 21.75% $381.00
Company Price Analyst Target Market Cap P/E Ratio Dividend per Share Dividend Yield Price / LTM Sales
RGEN
Repligen
$141.51 $183.13 $8B 633.44x $0.00 0% 12.24x
BAX
Baxter International
$30.71 $38.80 $15.8B 167.20x $0.17 3% 1.32x
CATX
Perspective Therapeutics
$2.5600 $14.3929 $189.6M -- $0.00 0% 16.57x
ICUI
ICU Medical
$141.64 $186.40 $3.5B -- $0.00 0% 1.45x
MASS
908 Devices
$5.60 $5.50 $197.8M -- $0.00 0% 3.20x
UFPT
UFP Technologies
$202.21 $381.00 $1.6B 26.61x $0.00 0% 3.12x
Company Total Debt / Total Capital Beta Debt to Equity Quick Ratio
RGEN
Repligen
21.06% 1.369 7.41% 5.56x
BAX
Baxter International
65.34% 0.052 -- 0.54x
CATX
Perspective Therapeutics
-- -1.032 -- --
ICUI
ICU Medical
44.61% 1.698 41.61% 0.92x
MASS
908 Devices
-- -5.739 -- 3.27x
UFPT
UFP Technologies
35.59% 3.826 10.09% 1.35x
Company Gross Profit Operating Income Return on Invested Capital Return on Common Equity EBIT Margin Free Cash Flow
RGEN
Repligen
$90.8M $6.6M -0.91% -1.16% 7.8% $10.6M
BAX
Baxter International
$861M $58M -2.68% -8.24% 2.32% $351M
CATX
Perspective Therapeutics
-- -$20.9M -- -- -- -$41.2M
ICUI
ICU Medical
$227.3M $46.1M -3.22% -5.75% 5.46% $13.6M
MASS
908 Devices
$9.1M -$11.2M -49.84% -49.84% -103.7% -$2.4M
UFPT
UFP Technologies
$42.1M $23.4M 14.28% 18.87% 15.6% $21.4M

Repligen vs. Competitors

  • Which has Higher Returns RGEN or BAX?

    Baxter International has a net margin of 3.45% compared to Repligen's net margin of 4.8%. Repligen's return on equity of -1.16% beat Baxter International's return on equity of -8.24%.

    Company Gross Margin Earnings Per Share Invested Capital
    RGEN
    Repligen
    53.65% $0.10 $2.5B
    BAX
    Baxter International
    32.8% $0.25 $20.2B
  • What do Analysts Say About RGEN or BAX?

    Repligen has a consensus price target of $183.13, signalling upside risk potential of 29.41%. On the other hand Baxter International has an analysts' consensus of $38.80 which suggests that it could grow by 26.35%. Given that Repligen has higher upside potential than Baxter International, analysts believe Repligen is more attractive than Baxter International.

    Company Buy Ratings Hold Ratings Sell Ratings
    RGEN
    Repligen
    10 5 0
    BAX
    Baxter International
    4 11 1
  • Is RGEN or BAX More Risky?

    Repligen has a beta of 1.207, which suggesting that the stock is 20.699% more volatile than S&P 500. In comparison Baxter International has a beta of 0.628, suggesting its less volatile than the S&P 500 by 37.167%.

  • Which is a Better Dividend Stock RGEN or BAX?

    Repligen has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Baxter International offers a yield of 3% to investors and pays a quarterly dividend of $0.17 per share. Repligen pays -- of its earnings as a dividend. Baxter International pays out -90.91% of its earnings as a dividend.

  • Which has Better Financial Ratios RGEN or BAX?

    Repligen quarterly revenues are $169.2M, which are smaller than Baxter International quarterly revenues of $2.6B. Repligen's net income of $5.8M is lower than Baxter International's net income of $126M. Notably, Repligen's price-to-earnings ratio is 633.44x while Baxter International's PE ratio is 167.20x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Repligen is 12.24x versus 1.32x for Baxter International. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    RGEN
    Repligen
    12.24x 633.44x $169.2M $5.8M
    BAX
    Baxter International
    1.32x 167.20x $2.6B $126M
  • Which has Higher Returns RGEN or CATX?

    Perspective Therapeutics has a net margin of 3.45% compared to Repligen's net margin of --. Repligen's return on equity of -1.16% beat Perspective Therapeutics's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    RGEN
    Repligen
    53.65% $0.10 $2.5B
    CATX
    Perspective Therapeutics
    -- -$0.61 --
  • What do Analysts Say About RGEN or CATX?

    Repligen has a consensus price target of $183.13, signalling upside risk potential of 29.41%. On the other hand Perspective Therapeutics has an analysts' consensus of $14.3929 which suggests that it could grow by 462.22%. Given that Perspective Therapeutics has higher upside potential than Repligen, analysts believe Perspective Therapeutics is more attractive than Repligen.

    Company Buy Ratings Hold Ratings Sell Ratings
    RGEN
    Repligen
    10 5 0
    CATX
    Perspective Therapeutics
    10 1 0
  • Is RGEN or CATX More Risky?

    Repligen has a beta of 1.207, which suggesting that the stock is 20.699% more volatile than S&P 500. In comparison Perspective Therapeutics has a beta of 1.112, suggesting its more volatile than the S&P 500 by 11.175%.

  • Which is a Better Dividend Stock RGEN or CATX?

    Repligen has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Perspective Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Repligen pays -- of its earnings as a dividend. Perspective Therapeutics pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios RGEN or CATX?

    Repligen quarterly revenues are $169.2M, which are larger than Perspective Therapeutics quarterly revenues of --. Repligen's net income of $5.8M is higher than Perspective Therapeutics's net income of -$40.2M. Notably, Repligen's price-to-earnings ratio is 633.44x while Perspective Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Repligen is 12.24x versus 16.57x for Perspective Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    RGEN
    Repligen
    12.24x 633.44x $169.2M $5.8M
    CATX
    Perspective Therapeutics
    16.57x -- -- -$40.2M
  • Which has Higher Returns RGEN or ICUI?

    ICU Medical has a net margin of 3.45% compared to Repligen's net margin of -3.78%. Repligen's return on equity of -1.16% beat ICU Medical's return on equity of -5.75%.

    Company Gross Margin Earnings Per Share Invested Capital
    RGEN
    Repligen
    53.65% $0.10 $2.5B
    ICUI
    ICU Medical
    36.08% -$0.97 $3.5B
  • What do Analysts Say About RGEN or ICUI?

    Repligen has a consensus price target of $183.13, signalling upside risk potential of 29.41%. On the other hand ICU Medical has an analysts' consensus of $186.40 which suggests that it could grow by 31.6%. Given that ICU Medical has higher upside potential than Repligen, analysts believe ICU Medical is more attractive than Repligen.

    Company Buy Ratings Hold Ratings Sell Ratings
    RGEN
    Repligen
    10 5 0
    ICUI
    ICU Medical
    3 1 0
  • Is RGEN or ICUI More Risky?

    Repligen has a beta of 1.207, which suggesting that the stock is 20.699% more volatile than S&P 500. In comparison ICU Medical has a beta of 0.870, suggesting its less volatile than the S&P 500 by 12.976%.

  • Which is a Better Dividend Stock RGEN or ICUI?

    Repligen has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. ICU Medical offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Repligen pays -- of its earnings as a dividend. ICU Medical pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios RGEN or ICUI?

    Repligen quarterly revenues are $169.2M, which are smaller than ICU Medical quarterly revenues of $629.8M. Repligen's net income of $5.8M is higher than ICU Medical's net income of -$23.8M. Notably, Repligen's price-to-earnings ratio is 633.44x while ICU Medical's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Repligen is 12.24x versus 1.45x for ICU Medical. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    RGEN
    Repligen
    12.24x 633.44x $169.2M $5.8M
    ICUI
    ICU Medical
    1.45x -- $629.8M -$23.8M
  • Which has Higher Returns RGEN or MASS?

    908 Devices has a net margin of 3.45% compared to Repligen's net margin of -103.33%. Repligen's return on equity of -1.16% beat 908 Devices's return on equity of -49.84%.

    Company Gross Margin Earnings Per Share Invested Capital
    RGEN
    Repligen
    53.65% $0.10 $2.5B
    MASS
    908 Devices
    48.37% -$0.56 $114.6M
  • What do Analysts Say About RGEN or MASS?

    Repligen has a consensus price target of $183.13, signalling upside risk potential of 29.41%. On the other hand 908 Devices has an analysts' consensus of $5.50 which suggests that it could fall by -1.79%. Given that Repligen has higher upside potential than 908 Devices, analysts believe Repligen is more attractive than 908 Devices.

    Company Buy Ratings Hold Ratings Sell Ratings
    RGEN
    Repligen
    10 5 0
    MASS
    908 Devices
    3 1 0
  • Is RGEN or MASS More Risky?

    Repligen has a beta of 1.207, which suggesting that the stock is 20.699% more volatile than S&P 500. In comparison 908 Devices has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

  • Which is a Better Dividend Stock RGEN or MASS?

    Repligen has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. 908 Devices offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Repligen pays -- of its earnings as a dividend. 908 Devices pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios RGEN or MASS?

    Repligen quarterly revenues are $169.2M, which are larger than 908 Devices quarterly revenues of $18.8M. Repligen's net income of $5.8M is higher than 908 Devices's net income of -$19.4M. Notably, Repligen's price-to-earnings ratio is 633.44x while 908 Devices's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Repligen is 12.24x versus 3.20x for 908 Devices. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    RGEN
    Repligen
    12.24x 633.44x $169.2M $5.8M
    MASS
    908 Devices
    3.20x -- $18.8M -$19.4M
  • Which has Higher Returns RGEN or UFPT?

    UFP Technologies has a net margin of 3.45% compared to Repligen's net margin of 11.37%. Repligen's return on equity of -1.16% beat UFP Technologies's return on equity of 18.87%.

    Company Gross Margin Earnings Per Share Invested Capital
    RGEN
    Repligen
    53.65% $0.10 $2.5B
    UFPT
    UFP Technologies
    29.19% $2.10 $532.1M
  • What do Analysts Say About RGEN or UFPT?

    Repligen has a consensus price target of $183.13, signalling upside risk potential of 29.41%. On the other hand UFP Technologies has an analysts' consensus of $381.00 which suggests that it could grow by 88.42%. Given that UFP Technologies has higher upside potential than Repligen, analysts believe UFP Technologies is more attractive than Repligen.

    Company Buy Ratings Hold Ratings Sell Ratings
    RGEN
    Repligen
    10 5 0
    UFPT
    UFP Technologies
    1 2 0
  • Is RGEN or UFPT More Risky?

    Repligen has a beta of 1.207, which suggesting that the stock is 20.699% more volatile than S&P 500. In comparison UFP Technologies has a beta of 1.100, suggesting its more volatile than the S&P 500 by 9.979%.

  • Which is a Better Dividend Stock RGEN or UFPT?

    Repligen has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. UFP Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Repligen pays -- of its earnings as a dividend. UFP Technologies pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios RGEN or UFPT?

    Repligen quarterly revenues are $169.2M, which are larger than UFP Technologies quarterly revenues of $144.1M. Repligen's net income of $5.8M is lower than UFP Technologies's net income of $16.4M. Notably, Repligen's price-to-earnings ratio is 633.44x while UFP Technologies's PE ratio is 26.61x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Repligen is 12.24x versus 3.12x for UFP Technologies. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    RGEN
    Repligen
    12.24x 633.44x $169.2M $5.8M
    UFPT
    UFP Technologies
    3.12x 26.61x $144.1M $16.4M

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Why Did Salesforce Stock Drop After a Strong Quarter?
Why Did Salesforce Stock Drop After a Strong Quarter?

Popular customer relationship management platform provider Salesforce (NYSE:CRM) has been…

Is Adobe Stock a Bargain With AI Tools Driving Growth?
Is Adobe Stock a Bargain With AI Tools Driving Growth?

The share price of American computer software company Adobe (NASDAQ:ADBE)…

Is Palantir Stock a Millionaire Maker?
Is Palantir Stock a Millionaire Maker?

Palantir (NASDAQ:PLTR) has shot upward over the last year and…

Stock Ideas

Buy
71
Is MSFT Stock a Buy?

Market Cap: $3.2T
P/E Ratio: 37x

Sell
46
Is AAPL Stock a Buy?

Market Cap: $3.1T
P/E Ratio: 34x

Buy
63
Is NVDA Stock a Buy?

Market Cap: $2.8T
P/E Ratio: 39x

Alerts

Sell
4
CABO alert for May 3

Cable One [CABO] is down 41.98% over the past day.

Buy
55
PDEX alert for May 3

Pro-Dex [PDEX] is down 32.02% over the past day.

Buy
91
TRUP alert for May 3

Trupanion [TRUP] is up 23.52% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock